Remdesivir Distribution Begins With More Questions Than Answers
Ethicists decry the government's opaque approach, highlighting the potential risks of a fast US FDA emergency authorization if supply isn't able to support demand following regulatory clearance. AmerisourceBergen is distributing the drug for the government, but within the Administration, no agency appears to want to take public responsibility for the decisions about where the doses of the COVID-19 treatment are sent.
You may also be interested in...
Gilead’s COVID treatment will be the first product tracked in a system that could eventually help allocate vaccines and other therapeutics.
Coronavirus Notebook: Remdesivir Supply Dwindles; US FDA Signs Another RWE Deal; Corning Gets BARDA Contract For Glass Vials
Dispatches from a world turned upside down also include changes in drug sample distribution guidelines and further reductions in the hours of FDA’s COVID hotline.
“We still try hard to get people to have a control group,” Bob Temple says in an interview. “Not everybody always wants to have a control group. We've been trying hard to do it.”